The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Cardiotoxicity of Cancer Therapy
Abstract
Because cancer is a leading cause of mortality in the United States, the number of therapeutic modalities available for the treatment of neoplastic processes has increased. This has resulted in a large number of patients being exposed to a wide variety of cancer therapy. Historically, it has been well recognized that antineoplastic agents may have adverse effects on multiple organs and normal tissues. The most commonly associated toxicities occur in tissues composed of rapidly dividing cells and may spontaneously reverse with minimal long-term toxicity. However, the myocardium consists of cells that have limited regenerative capability, which may render the heart susceptible to permanent or transient adverse effects from chemotherapeutic agents. Such toxicity encompasses a heterogeneous group of disorders, ranging from relatively benign arrhythmias to potentially lethal conditions such as myocardial ischemia/infarction and cardiomyopathy. In some instances, the pathogenesis of these toxic effects has been elucidated, whereas in others the precise etiology remains unknown. We review herein the various syndromes of cardiac toxicity that are reported to be associated with antineoplastic agents and discuss their putative mechanisms and treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,391
Citron, M. L., Berry, D. A., Cirrincione, C., Hudis, C., Winer, E. P., Gradishar, W. J., Davidson, N. E., Martino, S., Livingston, R., Ingle, J. N., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.081 · Cited by 1,564
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
Seidman, A. D., Hudis, C. A., Pierri, M. K., Shak, S., Paton, V. E., Ashby, M. A., Murphy, M., Stewart, S. J., & Keefe, D. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1215 · Cited by 1,563
Hoff, P. M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kuperminc, M., Maroun, J., Walde, D., Weaver, C., Harrison, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2282 · Cited by 1,130
McGuire, W. P., Rowinsky, E. K., Rosenshein, N. B., Grumbine, F. C., Ettinger, D. S., Armstrong, D. K., & Donehower, R. C. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-4-273 · Cited by 1,100
Van Cutsem, E., Twelves, C., Cassidy, J., Allman, D., Bajetta, E., Boyer, M., Bugat, R., Findlay, M., Frings, S., Jahn, M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.21.4097 · Cited by 1,032
United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
Soignet, S. L., Frankel, S. R., Douer, D., Tallman, M. S., Kantarjian, H., Calleja, E., Stone, R. M., Kalaycio, M., Scheinberg, D. A., Steinherz, P., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3852 · Cited by 826
Lipshultz, S. E., Lipsitz, S. R., Mone, S. M., Goorin, A. M., Sallan, S. E., Sanders, S. P., Orav, E. J., Gelber, R. D., & Colan, S. D. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506293322602 · Cited by 803
Batist, G., Ramakrishnan, G., Rao, C. S., Chandrasekharan, A., Gutheil, J., Guthrie, T., Shah, P., Khojasteh, A., Nair, M. K., Hoelzer, K., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1444 · Cited by 669
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
Swain, S. M., Whaley, F. S., Gerber, M. C., Weisberg, S., York, M., Spicer, D., Jones, S. E., Wadler, S., Desai, A., Vogel, C., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1318 · Cited by 664
Lipshultz, S. E., Rifai, N., Dalton, V. M., Levy, D. E., Silverman, L. B., Lipsitz, S. R., Colan, S. D., Asselin, B. L., Barr, R. D., Clavell, L. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035153 · Cited by 623
Fisher, B., Brown, A. M., Dimitrov, N. V., Poisson, R., Redmond, C., Margolese, R. G., Bowman, D., Wolmark, N., Wickerham, D. L., & Kardinal, C. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.9.1483 · Cited by 620
Gianni, L., Munzone, E., Capri, G., Fulfaro, F., Tarenzi, E., Villani, F., Spreafico, C., Laffranchi, A., Caraceni, A., & Martini, C. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.11.2688 · Cited by 553
Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy
Cardinale, D., Sandri, M. T., Martinoni, A., Tricca LabTech, A., Civelli, M., Lamantia, G., Cinieri, S., Martinelli, G., Cipolla, C. M., & Fiorentini, C. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00748-8 · Cited by 551
Serial Assessment of Doxorubicin Cardiotoxicity with Quantitative Radionuclide Angiocardiography
Alexander, J., Dainiak, N., Berger, H. J., Goldman, L., Johnstone, D., Reduto, L., Duffy, T., Schwartz, P., Gottschalk, A., Zaret, B. L., et al. (1979) · New England Journal of Medicine · doi:10.1056/nejm197902083000603 · Cited by 535
Harris, L., Batist, G., Belt, R., Rovira, D., Navari, R., Azarnia, N., Welles, L., Winer, E., & TLC D‐99 Study Group (2002) · Cancer · doi:10.1002/cncr.10201 · Cited by 512
Cardiotoxicity Associated With High-Dose Cyclophosphamide Therapy
Gottdiener, J. S. (1981) · Archives of Internal Medicine · doi:10.1001/archinte.141.6.758 · Cited by 486
Antman, K. H., Crowley, J. J., Balcerzak, S. P., Rivkin, S. E., Weiss, G. R., ELIAS, A. D., Natale, R. B., Cooper, R. M., Barlogie, B., & Trump, D. L. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.7.1276 · Cited by 478
Cardiac disturbances during the administration of taxol.
Rowinsky, E. K., McGuire, W. P., Guarnieri, T., Fisherman, J. S., Christian, M. C., & Donehower, R. C. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.9.1704 · Cited by 395
Predictive Value of Cardiac Troponin T in Pediatric Patients at Risk for Myocardial Injury
Lipshultz, S. E., Rifai, N., Sallan, S. E., Lipsitz, S. R., Dalton, V., Sacks, D. B., & Ottlinger, M. E. (1997) · Circulation · doi:10.1161/01.cir.96.8.2641 · Cited by 384
Speyer, J. L., Green, M. D., Kramer, E., Rey, M., Sanger, J., Ward, C., Dubin, N., Ferrans, V., Stecy, P., Zeleniuch-Jacquotte, A., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809223191203 · Cited by 356
Margolin, K. A., Rayner, A. A., Hawkins, M. J., Atkins, M. B., Dutcher, J. P., Fisher, R. I., Weiss, G. R., Doroshow, J. H., Jaffe, H. S., & Roper, M. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.4.486 · Cited by 346
Subclinical Late Cardiomyopathy After Doxorubicin Therapy for Lymphoma in Adults
Hequet, O., Le, Q. H., Moullet, I., Pauli, E., Salles, G., Espinouse, D., Dumontet, C., Thieblemont, C., Arnaud, P., Antal, D., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.033 · Cited by 340
Early anthracycline cardiotoxicity
Bristow, M. R., Thompson, P. D., Martin, R. P., Mason, J. W., Billingham, M. E., & Harrison, D. C. (1978) · The American Journal of Medicine · doi:10.1016/0002-9343(78)90802-1 · Cited by 334
ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.
Speyer, J. L., Green, M. D., Zeleniuch-Jacquotte, A., Wernz, J. C., Rey, M., Sanger, J., Kramer, E., Ferrans, V, Hochster, H., & Meyers, M. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.117 · Cited by 322
Van Cutsem, E., Findlay, M., Osterwalder, B., Kocha, W., Dalley, D., Pazdur, R., Cassidy, J., Dirix, L., Twelves, C., Allman, D., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1337 · Cited by 318
Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy
Cardinale, D., Sandri, M. T., Martinoni, A., Borghini, E., Civelli, M., Lamantia, G., Cinieri, S., Martinelli, G., Fiorentini, C., & Cipolla, C. M. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf170 · Cited by 313
Jassem, J., Pieńkowski, T., Płuzańska, A., Jelic, S., Gorbunova, V., Mrsic-Krmpotic, Z., Berzins, J., Nagykalnai, T., Wigler, N., Renard, J., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1707 · Cited by 308
Mitoxantrone: A New Anticancer Drug with Significant Clinical Activity
SHENKENBERG, T. D., & VON HOFF, D. D. (1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-105-1-67 · Cited by 305
Tomasz, M., & Palom, Y. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)00088-0 · Cited by 283
Safety of Treatment of Metastatic Breast Cancer With Trastuzumab Beyond Disease Progression
Tripathy, D., Slamon, D. J., Cobleigh, M., Arnold, A., Saleh, M., Mortimer, J. E., Murphy, M., & Stewart, S. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.557 · Cited by 280
Clinical Cardiac Tolerability of Trastuzumab
Perez, E. A., & Rodeheffer, R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.120 · Cited by 280
ELIAS, A. D., RYAN, L. M., Sulkes, A., Collins, J. M., Aisner, J., & Antman, K. H. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.9.1208 · Cited by 275
Swain, S. M., Whaley, F. S., Gerber, M. C., Ewer, M. S., Bianchine, J. R., & Gams, R. A. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1333 · Cited by 269
Clinical spectrum of anthracycline antibiotic cardiotoxicity.
Bristow, M. R., Billingham, M. E., Mason, J. W., & Daniels, J. R. (1978) · PubMed · Cited by 250
Bailar, J. C., Byar, D. P., & The veterans administration cooperative urological research group (1970) · Cancer · doi:10.1002/1097-0142(197008)26:2<257::aid-cncr2820260203>3.0.co;2-9 · Cited by 244
Effect of Arsenic Trioxide on QT Interval in Patients With Advanced Malignancies
Barbey, J. T., Pezzullo, J. C., & Soignet, S. L. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.009 · Cited by 230
DOLL, D. C., LIST, A. F., GRECO, F. A., HAINSWORTH, J. D., HANDE, K. R., & JOHNSON, D. H. (1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-105-1-48 · Cited by 225
Self-citationPhase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer.
Fossella, F. V., Lee, J. S., Murphy, W. K., Lippman, S. M., Calayag, M., Pang, A., Chasen, M., Shin, D. M., Glisson, B., & Benner, S. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.6.1238 · Cited by 221
Ohnishi, K., Yoshida, H., Shigeno, K., Nakamura, S., Fujisawa, S., Naito, K., Shinjo, K., Fujita, Y., Matsui, H., Takeshita, A., et al. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-11-200012050-00012 · Cited by 209
A reassessment of cardiac toxicity associated with Taxol.
Arbuck, S. G., Strauss, W. H., Rowinsky, E. K., Christian, M. C., Suffness, M., Adams, J., Oakes, M., McGuire, W. P., Reed, E., & Gibbs, H. H. (1993) · PubMed · Cited by 195
Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study.
Rezkalla, S., Kloner, R. A., Ensley, J., al-Sarraf, M., Revels, S., Olivenstein, A., Bhasin, S., Kerpel-Fronious, S., & Turi, Z. G. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.4.509 · Cited by 187
ACUTE LETHAL CARDITIS CAUSED BY HIGH-DOSE COMBINATION CHEMOTHERAPY
Appelbaum, F., Strauchen, J., Graw, R., Savage, D., Kent, K., Ferrans, V., & Herzig, G. (1976) · The Lancet · doi:10.1016/s0140-6736(76)90151-3 · Cited by 176
Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer.
Francis, P., Schneider, J., Hann, L., Balmaceda, C., Barakat, R., Phillips, M., & Hakes, T. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.11.2301 · Cited by 167
5-Fluorouracil cardiotoxicity.
Lomeo, A. M., Avolio, C., Iacobellis, G., & Manzione, L. (1990) · PubMed · Cited by 157
Blackard, C. E., DOE, R. P., Mellinger, G. T., & Byar, D. P. (1970) · Cancer · doi:10.1002/1097-0142(197008)26:2<249::aid-cncr2820260202>3.0.co;2-7 · Cited by 152
Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity.
Herman, E. H., Lipshultz, S. E., Rifai, N., Zhang, J., Papoian, T., YU, Z., Takeda, K., & Ferrans, V. J. (1998) · PubMed · Cited by 151
High-Dose Ifosfamide Is Associated with Severe, Reversible Cardiac Dysfunction
Quezado, Z., Wilson, W. H., Cunnion, R. E., Parker, M. M., Reda, D., Bryant, G., & Ognibene, F. P. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-1-199301010-00006 · Cited by 144
Bajetta, E., Bartolomeo, M. D., Mariani, L., Cassata, A., Artale, S. A., Frustaci, S., Pinotti, G., Bonetti, A. V., Carreca, I. U., Biasco, G., et al. (2004) · Cancer · doi:10.1002/cncr.11910 · Cited by 137
Hayakawa, H., Komada, Y., Hirayama, M., Hori, H., Ito, M., & Sakurai, M. (2001) · Medical and Pediatric Oncology · doi:10.1002/mpo.1155 · Cited by 130
Cardiotoxic Effects of 5-Fluorouracil in the Guinea Pig
Matsubara, I., Kamiya, J., & Imai, S. (1980) · The Japanese Journal of Pharmacology · doi:10.1016/s0021-5198(19)52945-6 · Cited by 121
Stoter, G., Koopman, A., Vendrik, C. P. J., Struyvenberg, A., Sleyfer, D. T., Willemse, P. H. B., Koops, H. S., van Oosterom, A. T., Huinink, W. W. T. B., & Pinedo, H. M. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.8.1099 · Cited by 118
White, R. L., Schwartzentruber, D. J., Guleria, A. S., Macfarlane, M., White, D. E., Tucker, E. E., & Rosenberg, S. A. (1994) · Cancer · Cited by 108
Herman, E. H., Zhang, J., Rifai, N., Lipshultz, S. E., Hasinoff, B. B., Chadwick, D. P., Knapton, A. D., Chai, J., & Ferrans, V. J. (2001) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800100348 · Cited by 106
Prinzmetal's angina during 5-fluorouracil chemotherapy
Kleiman, N. S., Lehane, D. E., Geyer, C. E., Pratt, C. M., & Young, J. B. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90465-7 · Cited by 103
Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: A Phase II trial
Shields, A. F., Zalupski, M. M., Marshall, J. L., & Meropol, N. J. (2004) · Cancer · doi:10.1002/cncr.11925 · Cited by 66
Coronary spasm induced by capecitabine
Schnetzler, B., Popova, N., Lamb, C. C., & Sappino, A. P. (2001) · Annals of Oncology · doi:10.1023/a:1011152931300 · Cited by 60
Badorff, C., Noutsias, M., Kühl, U., & Schultheiß, H. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(96)00475-5 · Cited by 59
Acute chest pain syndrome during bleomycin infusions
White, D. A., Schwartzberg, L. S., Kris, M. G., & Bosl, G. J. (1987) · Cancer · doi:10.1002/1097-0142(19870501)59:9<1582::aid-cncr2820590909>3.0.co;2-# · Cited by 53
Non-Q-wave myocardial infarction associated with bleomycin and etoposide chemotherapy
Schwarzer, S., Eber, B., Greinix, H., & Lind, P. (1991) · European Heart Journal · doi:10.1093/eurheartj/12.6.748 · Cited by 53
Reversible cardiomyopathy induced by interferon.
Sonnenblick, M., Rosenmann, D., & Rosin, A. J. (1990) · BMJ · doi:10.1136/bmj.300.6733.1174 · Cited by 51
Cardiac effects of adjuvant therapy for early breastcancer
Theodoulou, M., & Seidman, A. D. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.08.024 · Cited by 49
Nousiainen, T., Vanninen, E. J., Jantunen, E., Remes, J., RITANEN, E., Vuolteenaho, O. J., & Hartikainen, J. E. K. (2001) · Clinical Science · doi:10.1042/cs1010601 · Cited by 45
Use of paclitaxel in patients with pre-existing cardiomyopathy: A review of our experience
Gollerkeri, A. M., Harrold, L., Rose, M. G., Jain, D., & Burtness, B. A. (2001) · International Journal of Cancer · doi:10.1002/ijc.1295 · Cited by 33
Lethal Cardiac Toxicity after Cisplatin and 5-Fluorouracil Chemotherapy
Martín, M., Díaz‐Rubio, E., Furió, V., Blázquez, J., Almenarez, J., & Fariña, J. (1989) · American Journal of Clinical Oncology · doi:10.1097/00000421-198906000-00010 · Cited by 27
Phase-I trial of Ultrapure? human leukocyte interferon in human malignancy
Budd, G. T., Bukowski, R. M., Miketo, L., et al. (1984) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00255907 · Cited by 23
Biological-response modifier--induced emergencies.
Crum, E. D. (1989) · PubMed · Cited by 11
Cited by
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw211 · Cited by 2,544
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.654 · Cited by 1,795
Mulrooney, D. A., Yeazel, M. W., Kawashima, T., Mertens, A. C., Mitby, P., Stovall, M., Donaldson, S. S., Green, D. M., Sklar, C. A., Robison, L. L., et al. (2009) · BMJ · doi:10.1136/bmj.b4606 · Cited by 1,166
Cardiovascular Complications of Cancer Therapy: Diagnosis, Pathogenesis, and Management
Yeh, E. T. H., Tong, A. T., Lenihan, D. J., Yusuf, S. W., Swafford, J., Champion, C., Durand, J.-B., Gibbs, H., Zafarmand, A. A., & Ewer, M. S. (2004) · Circulation · doi:10.1161/01.cir.0000133187.74800.b9 · Cited by 843
Lipshultz, S. E., Adams, M. J., Colan, S. D., Constine, L. S., Herman, E. H., Hsu, D. T., Hudson, M. M., Kremer, L. C., Landy, D. C., Miller, T. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e3182a88099 · Cited by 612
Metadata
- Authors
- Floyd, J. D., Nguyen, D. T., Lobins, R. L., Bashir, Q., Doll, D. C., & Perry, M. C.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-10-20
- Volume
- 23
- Issue
- 30
- Pages
- 7685-7696
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2056918035
- Cited by
- 372
- References
- 67
- FWCI
- 7.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.